IGC PHARMA (Alzheimer’s Disease with Agitation)
This is a trial of the safety and efficacy of IGC-AD1 on Agitation in Participants with Dementia due to Alzheimer’s Disease.
Inclusion Criteria:
- 60 years of age and above
- Diagnosis of probable Alzheimer’s Disease
- Clinically significant agitation, must have a caregiver who can comply with required procedures
What to Expect
Participants will receive either IGC-AD1 or a placebo as an oral tincture. A placebo looks like the study drug but contains no real medicine. After 6 weeks, participants may have the opportunity to enroll in an open-label extension study, where ACP-204 will be administered (no placebo)
For more information click the link below or contact Tiffany Hoefler at thoefler@dentinstitute.com or 716-961-9219